Cantor keeps USD 22.00 target for Omeros stock

Published on 10/27/2026 at 22:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omeros expects USD 37.28 million in Q3 revenue on November 12, 2026. Omeros stock costs EUR 15.75 on October 27, 2026.

Analyst target remains unchanged

Cantor Fitzgerald maintained its USD 22.00 Omeros target on October 26, 2026.
MarketBeat estimates Q3 2026 revenue at USD 37.28 million for November 12, 2026.
Omeros stock costs EUR 15.75 at Lang & Schwarz on October 27, 2026 at 10:44 p.m. CEST.
Omeros has a USD 1.3 billion market capitalization as of October 27, 2026.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) faces a USD 22.00 price target from Cantor Fitzgerald, which maintained its view on October 26, 2026, as reported by Globe and Mail. At Lang & Schwarz, the stock was trading at EUR 15.75 on October 27, 2026 at 10:44 p.m. CEST.

Target leaves room for a rebound

Cantor Fitzgerald's USD 22.00 target stands 25.79 percent above Omeros's USD 17.49 Nasdaq price at 4:00 p.m. EDT on October 27, 2026. The target and the current quote are separate currency measures, so the euro quotation is not used for that calculation.

The analyst rating remains Overweight. A separate MarketBeat report dated October 16, 2026 said Cantor Fitzgerald had reiterated the rating and USD 22.00 target.

November 12 sets the next test

Omeros is estimated to report third-quarter 2026 results on November 12, 2026, after the market closes, with a conference call scheduled for 4:30 p.m. ET. MarketBeat lists consensus revenue of USD 37.28 million and consensus earnings per share of USD 0.03 for that quarter.

Q2 revenue provides the benchmark

For the second quarter of 2026, Omeros reported revenue of USD 28.53 million and adjusted earnings per share of USD 0.02, according to the same MarketBeat report. The revenue estimate for the next quarter is therefore USD 8.75 million higher, while the earnings comparison moves from an adjusted actual of USD 0.02 to a consensus estimate of USD 0.03.

Nasdaq valuation and range

Omeros had a market capitalization of USD 1.3 billion and a price-to-earnings ratio of 10.17 as of October 27, 2026. Its Nasdaq 52-week range was USD 6.24 to USD 21.24 on that date, placing the USD 17.49 quote 17.70 percent below the high. Trading volume reached 894,354 shares.

Stock price and investor view

Omeros is a biotechnology company focused on therapies involving complement, immune and coagulation systems. The company reported its second-quarter figures on August 12, 2026, creating a clear financial reference point before the November report.

Omeros was trading at EUR 15.75 at Lang & Schwarz on October 27, 2026 at 10:44 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Omeros stock.